CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214.

Hdl Handle:
http://hdl.handle.net/10034/620460
Title:
CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214.
Authors:
Benoit, Bernice M; Jariwala, Neha; O'Connor, Geraldine M; Oetjen, Landon; Whelan, Timothy M; Werth, Adrienne; Troxel, Andrea B; Sicard, Helene; Zhu, Lisa; Miller, Christopher; Takeshita, Junko; McVicar, Daniel W; Kim, Brian S; Rook, Alain H; Wysocka, Maria
Abstract:
Sézary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), is associated with a significantly shorter life expectancy compared to skin-restricted mycosis fungoides. Early diagnosis of SS is, therefore, key to achieving enhanced therapeutic responses. However, the lack of a biomarker(s) highly specific for malignant CD4+ T cells in SS patients has been a serious obstacle in making an early diagnosis. We recently demonstrated the high expression of CD164 on CD4+ T cells from Sézary syndrome patients with a wide range of circulating tumor burdens. To further characterize CD164 as a potential biomarker for malignant CD4+ T cells, CD164+ and CD164−CD4+ T cells isolated from patients with high-circulating tumor burden, B2 stage, and medium/low tumor burden, B1–B0 stage, were assessed for the expression of genes reported to differentiate SS from normal controls, and associated with malignancy and poor prognosis. The expression of Sézary signature genes: T plastin, GATA-3, along with FCRL3, Tox, and miR-214, was significantly higher, whereas STAT-4 was lower, in CD164+ compared with CD164−CD4+ T cells. While Tox was highly expressed in both B2 and B1–B0 patients, the expression of Sézary signature genes, FCRL3, and miR-214 was associated predominantly with advanced B2 disease. High expression of CD164 mRNA and protein was also detected in skin from CTCL patients. CD164 was co-expressed with KIR3DL2 on circulating CD4+ T cells from high tumor burden SS patients, further providing strong support for CD164 as a disease relevant surface biomarker.
Affiliation:
University of Chester; Department of Dermatology, Perelman School of Medicine University of Pennsylvania Philadelphia USA
Citation:
Benoit, B. M., Jariwala, N., O'Connor, G., Oetjen, L. K., Whelan, T. M., Werth, A.,.... Wysocka, M. (2017). CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214. Archives of Dermatological Research, 309(1),11-19.
Publisher:
SpringerLink
Journal:
Archives of Dermatological Research
Publication Date:
Jan-2017
URI:
http://hdl.handle.net/10034/620460
DOI:
10.1007/s00403-016-1698-8
Additional Links:
http://link.springer.com/article/10.1007%2Fs00403-016-1698-8
Type:
Article
Language:
en
Description:
The final publication is available at Springer via http://dx.doi.org/10.1007/s00403-016-1698-8
ISSN:
0340-3696
EISSN:
1432-069X
Appears in Collections:
Biological Sciences

Full metadata record

DC FieldValue Language
dc.contributor.authorBenoit, Bernice Men
dc.contributor.authorJariwala, Nehaen
dc.contributor.authorO'Connor, Geraldine Men
dc.contributor.authorOetjen, Landonen
dc.contributor.authorWhelan, Timothy Men
dc.contributor.authorWerth, Adrienneen
dc.contributor.authorTroxel, Andrea Ben
dc.contributor.authorSicard, Heleneen
dc.contributor.authorZhu, Lisaen
dc.contributor.authorMiller, Christopheren
dc.contributor.authorTakeshita, Junkoen
dc.contributor.authorMcVicar, Daniel Wen
dc.contributor.authorKim, Brian Sen
dc.contributor.authorRook, Alain Hen
dc.contributor.authorWysocka, Mariaen
dc.date.accessioned2017-03-31T10:00:02Z-
dc.date.available2017-03-31T10:00:02Z-
dc.date.issued2017-01-
dc.identifier.citationBenoit, B. M., Jariwala, N., O'Connor, G., Oetjen, L. K., Whelan, T. M., Werth, A.,.... Wysocka, M. (2017). CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214. Archives of Dermatological Research, 309(1),11-19.en
dc.identifier.issn0340-3696-
dc.identifier.doi10.1007/s00403-016-1698-8-
dc.identifier.urihttp://hdl.handle.net/10034/620460-
dc.descriptionThe final publication is available at Springer via http://dx.doi.org/10.1007/s00403-016-1698-8en
dc.description.abstractSézary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), is associated with a significantly shorter life expectancy compared to skin-restricted mycosis fungoides. Early diagnosis of SS is, therefore, key to achieving enhanced therapeutic responses. However, the lack of a biomarker(s) highly specific for malignant CD4+ T cells in SS patients has been a serious obstacle in making an early diagnosis. We recently demonstrated the high expression of CD164 on CD4+ T cells from Sézary syndrome patients with a wide range of circulating tumor burdens. To further characterize CD164 as a potential biomarker for malignant CD4+ T cells, CD164+ and CD164−CD4+ T cells isolated from patients with high-circulating tumor burden, B2 stage, and medium/low tumor burden, B1–B0 stage, were assessed for the expression of genes reported to differentiate SS from normal controls, and associated with malignancy and poor prognosis. The expression of Sézary signature genes: T plastin, GATA-3, along with FCRL3, Tox, and miR-214, was significantly higher, whereas STAT-4 was lower, in CD164+ compared with CD164−CD4+ T cells. While Tox was highly expressed in both B2 and B1–B0 patients, the expression of Sézary signature genes, FCRL3, and miR-214 was associated predominantly with advanced B2 disease. High expression of CD164 mRNA and protein was also detected in skin from CTCL patients. CD164 was co-expressed with KIR3DL2 on circulating CD4+ T cells from high tumor burden SS patients, further providing strong support for CD164 as a disease relevant surface biomarker.en
dc.language.isoenen
dc.publisherSpringerLinken
dc.relation.urlhttp://link.springer.com/article/10.1007%2Fs00403-016-1698-8en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectSézary syndromeen
dc.subjectKIR3DL2en
dc.titleCD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214.en
dc.typeArticleen
dc.identifier.eissn1432-069X-
dc.contributor.departmentUniversity of Chester; Department of Dermatology, Perelman School of Medicine University of Pennsylvania Philadelphia USAen
dc.identifier.journalArchives of Dermatological Researchen
dc.date.accepted2016-10-12-
or.grant.openaccessYesen
rioxxterms.funderTranslational Research Grant from the Leukemia and Lymphoma Societyen
rioxxterms.identifier.projectExternal fundingen
rioxxterms.versionAMen
rioxxterms.licenseref.startdate2018-01-31-
This item is licensed under a Creative Commons License
Creative Commons
All Items in ChesterRep are protected by copyright, with all rights reserved, unless otherwise indicated.